HK Stock Market Move | INNOVENT BIO (01801) surged over 6% in early trading, with a net profit growth exceeding 50% year-on-year in the first half of the year. The revenue target for 2030 is set at 35 billion to 40 billion yuan.

INNOVENT BIO (01801) opened over 6% higher and, as of the time of writing, is up 6.49%, trading at HKD 106.6, with a transaction volume of HKD 28.7287 million. On the news front, INNOVENT BIO released its interim results for 2026, measured according to International Financial Reporting Standards (IFRS): total revenue reached RMB 8.618 billion, an increase of 44.8% year-on-year, with product revenue of RMB 8.202 billion, up 56.7% year-on-year; profit for the period was RMB 1.253 billion, a year-on-year increase of 50.2%, with net profit for the first half having already surpassed the total for 2025. This robust performance is attributed to the ongoing effectiveness of its "dual-engine" strategy focused on oncology and chronic diseases. Currently, the company's commercial product portfolio has expanded to 20 products. In this semiannual report, INNOVENT BIO also clarified its development goals for 2030, aiming to achieve total revenue of RMB 35 billion to 40 billion by that year. In terms of global innovation, the company plans to advance at least 5 molecules into global multi-center Phase III studies and to achieve product launches in key Western markets by 2030, with overseas product revenue beginning to contribute. Additionally, INNOVENT BIO officially announced the initiation of its third major strategic transformation: transitioning from a leading biopharmaceutical company in China to a top-tier biopharmaceutical company with global competitiveness.